Pharmaceuticals company Aurobindo Pharma announced Q2FY27 results Standalone Financial Highlights: Revenue from Operations: For Q2FY27, revenue stands at Rs 31,773.3 million, showing a QoQ growth of 13.50% compared to Rs 27,995.1 million in Q1FY27 and a YoY growth of 16.39% compared to Rs 27,299.3 million in Q2FY26. For H1FY27, revenue stands at Rs 59,768.4 million, which is an 8.14% YoY increase from Rs 55,267.6 million in H1FY26. Total Income: For Q2FY27, total income reached Rs 32,801.3 million, up 7.85% QoQ from Rs 30,414.0 million in Q1FY27 and up 13.52% YoY from Rs 28,894.5 million in Q2FY26. For H1FY27, total income stands at Rs 63,215.3 million, registering a YoY growth of 9.56% against Rs 57,700.5 million in H1FY26. Profit Before Tax (PBT): For Q2FY27, PBT from continuing operations is Rs 9,709.5 million, declining by 3.68% QoQ compared to Rs 10,080.8 million in Q1FY27, but increasing by 28.36% YoY compared to Rs 7,564.1 million in Q2FY26. For H1FY27, PBT stands at Rs 19,790.3 million, marking a 31.16% YoY increase from Rs 15,088.2 million in H1FY26. Profit After Tax (PAT): For Q2FY27, total operations PAT is Rs 7,235.8 million, down 1.85% QoQ against Rs 7,372.2 million in Q1FY27, but up 24.46% YoY compared to Rs 5,813.7 million in Q2FY26. For H1FY27, PAT stands at Rs 14,608.0 million, representing a YoY increase of 28.08% from Rs 11,405.0 million in H1FY26. Earnings Per Share (EPS): For Q2FY27, basic EPS for total operations is Rs 12.58, down 1.33% QoQ from Rs 12.75 in Q1FY27, but up 25.67% YoY from Rs 10.01 in Q2FY26. For H1FY27, basic EPS is Rs 25.33, indicating a YoY increase of 28.97% against Rs 19.64 in H1FY26. Consolidated Financial Highlights: Revenue from Operations: For Q2FY27, revenue stands at Rs 1,02,632.9 million, a QoQ growth of 12.16% compared to Rs 91,503.5 million in Q1FY27 and a YoY growth of 23.87% against Rs 82,857.0 million in Q2FY26. For H1FY27, revenue is Rs 1,94,136.4 million, showing a YoY expansion of 20.18% over Rs 1,61,538.4 million in H1FY26. Total Income: For Q2FY27, total income reached Rs 1,04,315.1 million, rising 10.80% QoQ from Rs 94,145.8 million in Q1FY27 and 24.09% YoY from Rs 84,062.9 million in Q2FY26. For H1FY27, total income stands at Rs 1,98,460.9 million, up 21.17% YoY compared to Rs 1,63,793.4 million in H1FY26. Profit Before Tax (PBT): For Q2FY27, PBT is Rs 16,876.7 million, gaining 11.39% QoQ from Rs 15,150.9 million in Q1FY27 and expanding 32.27% YoY from Rs 12,759.2 million in Q2FY26. For H1FY27, PBT reached Rs 32,027.7 million, reflecting a YoY increase of 29.00% over Rs 24,827.2 million in H1FY26. Profit After Tax (PAT): For Q2FY27, PAT is Rs 11,238.4 million, which is an 8.90% increase QoQ over Rs 10,320.3 million in Q1FY27 and a 32.51% increase YoY from Rs 8,481.3 million in Q2FY26. For H1FY27, PAT reached Rs 21,558.8 million, showing a 28.91% YoY growth against Rs 16,723.3 million in H1FY26. Earnings Per Share (EPS): For Q2FY27, basic EPS stands at Rs 19.57, increasing 9.57% QoQ from Rs 17.86 in Q1FY27 and 33.95% YoY from Rs 14.61 in Q2FY26. For H1FY27, basic EPS is Rs 37.52, expanding 30.23% YoY over Rs 28.81 in H1FY26. K. Nithyananda Reddy, Vice-Chairman & Managing Director, said: “We are pleased to deliver a strong performance in Q2, reflecting the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio. Our growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future. As we advance our strategic priorities, we remain focused on sustainable growth, financial discipline and creating long-term value for our stakeholders, while continuing to expand access to quality and affordable healthcare worldwide.” Result PDF